Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

(RTTNews) - The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

Invitae has launched a cancer blood test designed to detect the minimal residual disease left over from solid tumors to help gauge a patient’s risk of recurrence and track their response to treatments ...

Invitae offers testing for hundreds of genes, covering hereditary cancers, epilepsy, arrhythmias, and more. Invitae Corporation, a genetic testing company based in San Francisco, has a lofty goal—to ...

Just two weeks after filing for a $100 million initial public offering, ArcherDx agreed to be acquired by Invitae for up-to-approximately $1.4 billion, in a deal the companies said would create a ...